A New Drug to Manage Resistant Chronic Pain Monday, April 30,
2012 TAU develops "BL-7050" to ease the neuropathic pain of
millions of sufferers Neuropathic pain, caused by nerve or
tissue damage, is the culprit behind many cases of chronic pain.
It can be the result of an accident or caused by a variety of
medical conditions and diseases such as tumors, lupus, and
diabetes. Typically resistant to common types of pain management
including ibuprofen and even morphine, neuropathic pain can lead
to lifelong disability for many sufferers. Now a drug developed
by Tel Aviv University researchers, known as BL-7050, is
offering new hope to patients with neuropathic pain. Developed
by Prof. Bernard Attali and Dr. Asher Peretz of TAU's Department
of Physiology and Pharmacology at the Sackler Faculty of
Medicine, the medication inhibits the transmission of pain
signals throughout the body. In both in-vitro and in-vivo
experiments measuring electrical activity of neurons, the
compound has been shown to prevent the hyper-e